Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.

Pharmacogenomics - 1 Oct 2010

Ruiter Rikje, Bijl Monique J, van Schaik Ron H N, Berns Els M J J, Hofman Albert, Coebergh Jan-Willem W, van Noord Charlotte, Visser Loes E, Stricker Bruno H Ch

Abstract excerpt

AIMS: Variant alleles of the CYP2C19 gene were recently associated with survival in breast cancer patients on tamoxifen therapy. CYP2C19 is one of the enzymes involved in the metabolism of tamoxifen into active metabolites. We investigated the hypothesis that CYP2C19*2 and *3 variants, known for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Breast Neoplasms
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Follow-Up Studies

Share to Predictive Value of Tests

Share to Survival Rate

Share to Tamoxifen

Source

Identifiers

PMID: 21047200
DOI: 10.2217/pgs.10.112

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21047200-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.PMID 21047200Read ↗

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.Semantic proximity Read ↗

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.Semantic proximity Read ↗

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.Semantic proximity Read ↗

Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.Semantic proximity Read ↗

Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen TherapySemantic proximity Read ↗

CYP2C19*17 is associated with decreased breast cancer risk.Semantic proximity Read ↗

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.Semantic proximity Read ↗

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.Semantic proximity Read ↗

Impaired tamoxifen metabolism reduces survival in familial breast cancer patients.Semantic proximity Read ↗

The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.Semantic proximity Read ↗

CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.Semantic proximity Read ↗

Genetic polymorphisms of the CYP19A1 gene and breast cancer survival.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.